Home > About Abraxis Oncology > Who We Are

Who We Are

Abraxis™ Oncology is the proprietary pharmaceuticals division of Abraxis BioScience, LLC, an integrated global biopharmaceutical company. Abraxis Oncology is dedicated to the discovery and development of novel cancer therapies that target tumor biological pathways. Our focus is to challenge current standards and develop next-generation therapies that revolutionize the treatment of cancer. Through innovative science and creative thinking, Abraxis Oncology is redefining cancer therapy as we know it. It is our hope that the discovery of new technologies and new compounds will improve survival, as well as tolerability, across a range of tumor types.

04/15/08 - Abraxis BioScience Presents New Preclinical Data Demonstrating Eradication of Large Orthotopic Breast Tumors and Metastasis with Combined nab-Paclitaxel (ABRAXANE(R)) and Bevacizumab (Avastin(R)) Therapy
04/09/08 - Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
04/04/07 - Abraxis BioScience Acquires Shimoda Biotech and Platco Technologies

Abraxis Oncology is a division of Abraxis BioScience, LLC. AO 997/268353 August 2008
All Abraxis BioScience, LLC corporate names (eg, ABRAXIS, ABRAXIS ONCOLOGY, ABRAXIS BIOSCIENCE, and their logos), names of services, and names of products (eg, ABRAXANE^® and the ABRAXANE logo) referred to herein are trade names, service marks and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions, or its affiliates, unless otherwise noted.